Clinical Trial Update: Study of ALTO-101 in Patients With Schizophrenia [Phase 2]

View source ↗

Summary

ALTO-101 is being studied in a Phase 2 trial for schizophrenia with cognitive impairment, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Schizophrenia

Drugs mentioned

• ALTO-101

Snippet

Sponsor: Alto Neuroscience | Conditions: Schizophrenia, Cognitive Impairment | Phase 2 | Status: RECRUITING